Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: 5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells

Fig. 1

Reduction effect of sorafenib and 5-methoxytryptophan (5-MTP) on the cell viability and proliferation of Lewis lung cancer (LLC) cells. The viability of LLC cells was reduced by sorafenib (A) or 5-MTP (B) treatments in cytotoxicity assay. The proliferation of LLC cells was inhibited by sorafenib (C) or 5-MTP (D) treatments in colony forming assay. Asterisks indicate a significant difference in drug-treated cells at indicated concentrations singly compared to DMSO-treated cells. *P < 0.05

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us